Le Lézard
Classified in: Health, Business
Subject: ATY

NEVRO HOLDINGS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nevro Corp. - NVRO



NEW ORLEANS, Sept. 21, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp. (NYSE: NVRO), if they purchased the Company's shares between January 8, 2018 and July 12, 2018, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.

Get Help

Nevro investors should visit us at https://www.claimsfiler.com/cases/view-nevro-corporation-securities-litigation or call toll-free (844) 367-9658.  Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.  

About the Lawsuit

Nevro and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On July 10, 2018, analysts reported that a tentative court ruling in patent litigation involving Nevro nullified at least five patents related to the Company's "proprietary" HF10 pain therapy and Senza delivery systems, which resulted in some analysts downgrading the Company.  Then, on July 13, 2018, the Company disclosed pre-market that it had terminated the employment of James Alecxih, Vice President, Worldwide Sales.

News of both events caused the price of Nevro's shares to plummet, wiping out over $650 million in market capitalization.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

 

SOURCE ClaimsFiler


These press releases may also interest you

at 05:15
The "Healthcare Claims Management Market by Component (Software, and Services), Delivery Mode (On-Premise, and Cloud Based), Type (Integrated, and Standalone), End User (Healthcare Payers, Providers) - Global Forecast to 2023" report has been added...

at 05:00
HSA administrators, Clarity Benefit Solutions, shares five ways to maintain HSA eligibility. Once HSA plans are in place, it is imperative to ensure that employees remain eligible for their plans. This can be quite challenging with ever-evolving...

at 03:56
A recent study published in iScience researchers at Kanazawa University describes the role of a molecule, Netrin, in creating borders inside the brain to compartmentalize the functions of the brain.      (Photo:...

at 03:00
Medivir AB  today announces that the transformation to focus the company's internal resources on its clinical development projects has now been completed. Redundancies, mainly within research and administration, are reducing the number of employees...

at 03:00
SynTech Nutrition's vision of total transparency and high-dosage formulations separates it from the rest of the sport supplement industry. "People should know what they are buying and consuming," said Bob Wigman, director...

at 02:13
BioArctic AB (publ) announced today that BioArctic and its partner AbbVie have received U.S. Federal Trade Commission (FTC) clearance to license BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease and other potential indications...




News published on 21 september 2018 at 22:50 and distributed by: